Piramal Pharma Q4FY26 Revenue ₹2,752 Cr, FY26 ₹8,869 Cr
Piramal Pharma Ltd announced its Q4 and full-year FY26 standalone and consolidated financial results. For Q4FY26, revenue from operations was ₹2,752 crore, flat year-on-year, while full-year FY26 revenue was ₹8,869 crore, a 3% decline. EBITDA for Q4FY26 stood at ₹507 crore (-16% YoY) and for FY26 at ₹1,135 crore (-28% YoY). The company reported a Q4FY26 PAT after exceptional items of (₹9) crore and a full-year PAT of (₹326) crore, including a ₹176 crore impairment loss on intangible assets. Revenue was impacted by inventory destocking and slower early-stage order inflows. Despite challenges, the company exited FY26 with momentum, expecting growth in FY27 across CDMO, CHG, and Consumer Healthcare businesses, driven by biopharma funding recovery, the Kenalog® acquisition, and e-commerce expansion. Capex of US$94 million was invested, and net debt remained stable.
Key Highlights
- Q4FY26 revenue was ₹2,752 Cr (0% YoY); FY26 revenue was ₹8,869 Cr (-3% YoY).
- Q4FY26 EBITDA declined 16% to ₹507 Cr; FY26 EBITDA fell 28% to ₹1,135 Cr.
- Company reported a Q4FY26 net loss of ₹9 Cr after a ₹176 Cr impairment.
- CDMO business shows recovery in H2FY26 with healthy RFP and order inflows.
- Kenalog® acquisition completed, expected to drive growth in the CHG business.